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1. Introduction  
The ubiquitin-proteasomal system (UPS) is critical for the regulation of protein homeostasis 
and is composed of the protein ubiquitination system and proteasomal degradation system. 
Protein ubiquitination is referred to the process that the small protein ubiquitin is covalently 
tagged to a specific substrate protein. Once a protein is ubiquitinated, its structural 
conformation, cellular location, and biological function will change accordingly, or it will be 
delivered into the 26S proteasome complex for degradation by specific proteases. The UPS is 
extensively involved in nearly all the important cell biological activities, such as cell 
metabolism, cell proliferation, glycogen synthesis, immunological process, organogenesis, 
etc. (Ciechanover, 1998; Haglund and Dikic, 2005; Kirkin and Dikic, 2010).  
The UPS system is also widely associated with various diseases, such as inflammation, 
arthritis, heart disease and cancers (Ciechanover et al., 2000). For example, the proteasome 
has emerged as a milestone target for cancer therapy, which was further demonstrated by 
the discovery of the proteasome inhibitor bortezomib for the therapy of multiple myeloma 
(Kisselev and Goldberg, 2001; Richardson et al., 2003). Recently, in addition to the 
proteasome, the protein ubiquitination pathway is also being developed as a novel target for 
anti-cancer drugs (Bedford et al., 2011 ; Colland, 2010). In this chapter, we will discuss  the 
UPS system, its biological implications, and associated targeted drug discovery for 
hematological malignancies. 
2. The ubiquitin-proteasomal system (UPS)  
The UPS is composed by at least 6 components, including ubiquitin (Ub), ubiquitin-
activating enzymes (UBA, E1), ubiquitin-conjugating enzymes (UBC, E2), ubiquitin ligases 
(E3), proteasomes, and deubiquitinases (Dub) (Figure 1). The substrate proteins are first 
tagged with a ubiquitin chain under the guidance of E1, E2 and E3, and the produced 
polyubiquitinated proteins are then transferred to 26S proteasomes where it is degraded by 
the 20S core particles. 
2.1 Ubiquitination 
Ubiquitin is a ubiquitinously expressed small protein composed of 76 amino acids and  
it plays a central role in the UPS system. It can be linked to a substrate protein with the  
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Fig. 1. The ubiquitination-proteasomal system (UPS). The UPS is composed of 6 
components, including ubiquitin (Ub), ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2), ubiquitin ligase (E3), deubiquitinases (Dub) and proteasomes.  
assistance of E1, E2, and E3, and can be removed from the target protein by Dubs. Ubiquitin 
is highly conserved and is expressed in most species but it is only found in eukaryotic 
organisms. This strong sequence conservation suggests that ubiquitin plays a very 
fundamental role in maintaining cell function and in species evolution. Actually, ubiquitin is 
involved in all aspects of cell biology and activities by regulating its extensive substrate 
proteins. Proteins will undergo turnover, translocation or conformational changes after they 
are covalently attached a ubiquitin, which is called ubiquitination, one of the most 
important post-translational modifications of proteins, where the carboxylic acid of the 
terminal glycine from the di-glycine motif in the activated ubiquitin forms an amide bond to 
the epsilon amine of the lysine in the substrate proteins (Ciechanover et al., 2000). In the 76 
amino acids, there are 6 lysine residues (K) including K6, K11, K27, K29, K33, K48, and K63 
as shown in Figure 2. These lysine residues are responsible for ubiquitin attachment to the 
target proteins. Theoretically, any lysine residues in a protein could be linked a ubiquitin, 
including ubiquitin itself, however, the biological function may differ and it depends on the 
ubiquitination status (Haglund and Dikic, 2005).  
Ubiquitination can be categorized into three classes based on the tagged ubiquitin (Haglund 
and Dikic, 2005; Ye and Rape, 2009): i) monoubiquitination: proteins are bound to a single 
ubiquitin, ii) multiubiquitination or poly-monoubiquitination: proteins are tagged with 
several single ubiquitin molecules; iii) polyubiquitination: proteins are attached with poly-
ubiquitin chains. These differences of ubiquitination on target proteins will regulate a 
variety of cellular processes, including protein degradation, signal transduction, membrane 
trafficking, DNA repair, chromatin remodelling, peroxisome biogenesis and viral budding 
(Ye and Rape, 2009). For example, polyubiquitin chain occurring at the 11th (K11) and 48th  
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Fig. 2. Protein ubiquitination and functional modulation. There are 7 lysine (K) residues in 
76 amino acids of ubiquitin and each could be further conjugated to a specific protein (A). 
Monoubiquitination (B) regulates protein conformation, cellular localization and protein 
interaction. Proteins tagged with polyubiquitin-chains occurring at K11 or K48 (C) are 
subject to degradation in the 26S proteasome. Polyubiquitination at K63 (D) activates NFB 
function and is involved in DNA repair. 
lysine (K48) of ubiquitin is mainly involved in protein degradation, but the K63 
polyubiquitination is mainly responsible for modification of protein function and involved 
in signal transduction, including regulation of NFκB signal pathway, DNA repair and 
targeting to the lysosome (Ye and Rape, 2009). For other proteins polyubiquintinated at K6, 
27, 29 or 33, whether they are involved in protein degradation or DNA repair is largely 
unknown (Ye and Rape, 2009)(Figure 2). 
2.2 Ubiquitining enzymes 
The ubiquitination process is an ATP-dependent enzymatic reaction and requires at least 3 
types of enzymes, including E1, E2 and E3 as described earlier, thus the ubiquitination 
process is alternatively known as the E1-E2-E3 cascade. In the process of ubiquitination, 
ubiquitin is first activated by E1 using ATP as an energy source to form a ubiquitin-
adenylate intermediate. Subsequently, the ubiquitin is transferred to the cysteine residue, 
the E1 active site, resulting in a thioester linkage between the C-terminal carboxyl group of 
ubiquitin and the E1 cysteine sulfhydryl group. Secondly, the activated ubiquitin is 
transferred from E1 to the cysteine of an E2 via a trans(thio)esterification reaction. Finally, 
the ubiquitination cascade creates an isopeptide bond between a lysine of the target protein 
and the C-terminal glycine of ubiquitin with the coordination of an E3 which identifies 
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specific recognition modules in the target protein and is capable of interaction with both E2 
and substrate (Ye and Rape, 2009). 
In human genome, there are only two genes encoding E1, whilst E2 is encoded by 60-100 
genes, and there are ~ 1000 different E3 genes (Deshaies and Joazeiro, 2009; Schulman and 
Harper, 2009). E1 activates ubiquitin at the top level, and transfers activated ubiquitin to 
different E2. E3s identify individual substrates and specifically ligate E2-Ub complex to a 
certain target protein. These enzymes form a hierarchical structure (Figure 3) and control the 
whole ubiquitination process. In this ubiquitination cascade, E1 binds to dozens of E2s, 
which bind to hundreds of E3s, and E3s specifically target thousands of substrate proteins.  
 
Fig. 3. E1, E2 and E3 form an enzymatic cascade for protein ubiquitination. One single E1 
initiates the whole ubiquitination process, by activating Ub and transferring it to E2. There 
are around 100 E2s in human. Each E2 will deliver activated Ub to one or several E3s which 
are a large family of around 1000 members. E3s specifically identify target proteins 
(substrates) and attach Ub to individual proteins. 
There are around 100 Dubs in human cells which cleave the ubiquitin-protein bonds thus 
regulating ubiquitin-dependent metabolic pathways (Colland, 2010). Polyubiquitinated 
proteins are deubiquitinated by Dubs immediately before degradation in the proteasome. In 
addition to ubiquitin recycling, Dubs are also involved in processing of ubiquitin 
precursors, in proofreading of protein ubiquitination and in disassembly of inhibitory 
ubiquitin chains. 
2.3 The proteasome system 
The 26S proteasome is a large protein complex with molecular weight more than 2000 
kilodalton and it is composed of one 20S core particle and two 19S regulatory particles, 
where the core particle is made up of two units (at the two ends) and two ǃ units (in the 
middle). Each of these units is composed of 7 ring-like subunits thus the total 28 subunits 
stack up to form a hollow cylinder (Figure 1). The subunits N-termini form a gate and 
serve as docking domains for the regulatory particles that block unregulated access of 
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substrates to the interior cavity (Smith et al., 2007). Proteins are lysed in the core particle but 
proteases are only found in the interior surface of the ǃ units, especially ǃ1, ǃ2 and ǃ5. 
Although these proteases share a common mechanism, each subunit dominants its 
distinctive catalytic activity due to interatomic contacts with local residues near the active 
sites of each subunit. ǃ1, ǃ2, and ǃ5 mainly present caspase-like, trypsin-like, and 
chymotrypsin-like activity, respectively. Each catalytic ǃ subunit also possesses a conserved 
lysine residue required for proteolysis. The proteasomes catalyze thousands of 
polyubiquitinated proteins, therefore, they are critical in regulatory protein function and cell 
activity. 
3. The UPS is extensively involved in hematological malignancies 
3.1 Protein ubiquitination in blood cancers 
Heavy ubiquitination levels of proteins, associated with overactivation of E1, have been 
observed both in leukemia cell lines and primary acute leukemia cells compared with the 
normal blood cells (Bedford et al., 2011; Xu et al., 2010). Additionally, blood cancer-specific 
proteins are also regulated by the UPS. For example, multiple myeloma (MM) tumor cells 
are recurrently associated with several chromosomal translocations that result in 
overexpression of transcription factors involved in the UPS pathway such as c-Maf, MafB, 
and fibroblast growth factor receptor 3 (FGFR3), which converge dysregulation of D-cyclins 
(Bergsagel and Kuehl, 2005). All these proteins could be poly-ubiquitinated and degraded in 
proteasomes. D-type cyclins are ubiquitinated under the coordination of SCF E3 ligase 
complex. The fibroblast growth factor receptor FGFR3 could also be ubiquitinated. In 
chronic leukemia, FGFR3 undergoes ubiquitination by c-Cbl, a RING finger domain-
containing E3 ligase. In chronic leukemia cells, the specific BAR-ABL fusion protein is 
ubiquitinated by c-CBL. Targeting at c-CBL, arsenic induces degradation of BCR-ABL (Mao 
et al., 2010). 
3.2 Ubiquitination enzymes and blood cancers 
E1 is responsible for the first step of the ubiquitination process by activating ubiquitin and is 
overexpressed in all leukemia and MM cell lines and primary samples. When E1 is knocked 
down, these leukemia and MM cells will go to apoptosis (Xu et al., 2010). Several E2s have 
been reported to be involved in MM development. For example, CDC34, the cell cycle 
regulator, is highly expressed in MM patient cells and cell lines in contrast to normal cells 
(Block et al., 2001). CDC34 has been implicated in the ubiquitination of p27 (Kip1), IκBǂ, Wee1, 
and MyoD, thus facilitating the degradation of these proteins by 26S proteasomes and 
modulating cell cycle progression. Inhibition of CDC34 enzymatic activity abrogates 
interleukin-6-induced protection against dexamethasone-induced MM cell apoptosis. 
Ubiquitin ligase E3s are the largest family in the UPS system. Various E3s are involved in 
leukemia, myeloma and lymphomas (Bernassola et al., 2008). For example, XIAP, the 
representative of the RING finger family of E3s, and Mdm2, the primary E3 ligase for p53 
ubiquitination (Jones et al., 2008), are overexpressed in various leukemic and myeloma cells 
and contribute to cell proliferation and anti-apoptotic activity. XIAP is also the most 
important enzyme that inhibits caspase-3, -6, and -7 activities and confers to drug resistance. 
Skp2 is another important E3 ligase. In CML cells, BCR-ABL fusion oncogene frequently up-
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regulate Skp2 expression via transcriptional activation, while treatment of Bcr-Abl kinase 
inhibitor imatinib led to G1 growth arrest accompanied with reduced Skp2 expression 
(Chen et al., 2011). SKP2 contributes to increased p27(Kip1) turnover, cell proliferation, and 
a poor prognosis in many tumor types (Zhan et al., 2007).  
3.3 Deubiquitinases and blood cancers 
Attached ubiquitin can be removed by a ubiquitin protease from targeted protein. USP9X is 
one of the most studied deubiquitinases and is probably involved in deubiquitination from 
oncoprotein MCL-1. Increased USP9X expression correlates with increased MCL1 protein in 
human follicular lymphomas and diffuse large B-cell lymphomas (Schwickart et al., 2010). 
Moreover, patients with multiple myeloma overexpressing USP9X have a poor prognosis. 
Knockdown of USP9X increases MCL1 polyubiquitination, which enhances MCL1 turnover 
and cell killing by the BH3 mimetic ABT-737, an inhibitor of MCL1 (Schwickart et al., 2010). 
Thus, USP9X has been identified as an effective prognostic and therapeutic target. Another 
important Dub is CYLD, which is a negative regulator of NFB. CYLD is located in the 16q12 
and its lower expression in MM cells is highly associated with deletion of 16q. In T cell 
leukemia, the Notch/Hes1 pathway sustains NFκB activation through CYLD repression. In 
MM cells highly expressing NFB, both the DNA copy number and protein expression of 
CYLD are markedly decreased. On the other hand, when treated with proteasome inhibitors 
such as MG132, CYLD will be accumulated in MM cells. CYLD presents as a tumor suppressor 
deubiquitinase and restoration of CYLD will sensitize cancer cell apoptosis (Jin et al., 2008). 
3.4 Proteasomes and blood cancers 
Several lines of evidence have shown that proteasome subunits in both leukemia and MM 
cells are abnormally higher than those normal or untransformed counterparts (Kumatori et 
al., 1990). Immunohistochemical staining shows considerably increased concentrations of 
proteasomes in leukemic cells from the bone marrow of patients with various types of 
leukemia and the predominant localization of these proteasomes in the nuclei. Moreover, 
enzyme immunoassay and Northern blot analysis indicate that the concentrations of 
proteasomes and their mRNA levels are consistently much higher in a variety of malignant 
human hematopoietic cell lines than in resting peripheral lymphocytes and monocytes from 
healthy adults. Proteasome expression is also increased in normal blood mononuclear cells 
during blastogenic transformation induced by phytohemagglutinin; their expression 
increased in parallel with induction of DNA synthesis and returned to the basal level with 
progress of the cell cycle. These findings strongly suggest that proteasomes are associated 
with cell cycle progression. Later studies demonstrated that proteasomes regulate a serial of 
cell cycle proteins, including p27, pRb, cyclin D, p53, p27, pro-apoptotic Bcl-2 family 
members, as well as the most important transcription factor in cell proliferation, NFB 
(Kisselev and Goldberg, 2001). Importantly, leukemia and myeloma cells are more sensitive 
to proteasome inhibitors. An early study found that the IC50 to inhibit cell proliferation in 
lymphoma is 5 times lower than normal T cells when treating cells with lactacystin, a classic 
and typical inhibitor of proteasomes (Delic et al., 1998). Another study indicated that B-CLL 
cells are about 10 times more sensitive to lactacystin than normal peripheral B lymphocytes. 
These results strongly suggest that proteasomes could be used as a drug target for myeloma 
and lymphoma therapy. 
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4. Discovery of bortezomib and its application in MM therapy 
4.1 Discovery of bortezomib as a treatment for myeloma  
Proteasomes are critical for cancer cells, therefore they could be used as a drug target for 
cancer therapy. Efforts are first made to develop such kinds of inhibitors for MM therapy. 
The seminal contribution came from Myogenic which developed a series of proteasome 
inhibitors, including MG132, one of the most common proteasome inhibitors currently used 
in research, and MG-341, which was renamed PS-341 and was further developed as a 
promising drug candidate for cancer therapy. PS-341 alone achieved an overall remission 
rate of 35% in refractory and/or relapse myeloma patients, when it was used in combination 
with other drugs such as cyclophosphamide and dexamethasone, the ORR could reach 
around 90% or greater. Following several large and multi-center clinical trials, PS-341 was 
approved by Food and Drug Administration of USA for MM in 2003, and for mantle cell 
lymphoma in 2006. PS-341 is now known as its general name bortezomib based on its 
chemical structure and is marketed as Velcade®. Recent studies also demonstrated that 
bortezomib might be particularly active against the active B cell-like diffuse large B cell 
lymphoma (ABC-DLBCL). ABC-DLBCL has a worse survival after upfront chemotherapy 
and is characterized by constitutive activation of the NFB pathway, which can inhibit 
chemotherapy. Although bortezomib alone has no activities on ABC-DLBCL, when 
administrated with chemotherapeutics, such as R-CHOP or DA-EPOCH-B, it achieved a 
superior overall response and survival according to a clinical study of 49 patients. Although 
ABC-DLBCL and GCB-DLBCL have similar poor outcome by regular chemotherapeutics, 
ABC-DLBCLs are more sensitive to bortezomib.  Bortezomib presented a high responsive 
rate (83% vs 13%) and median overall survival (10.8 vs 3.4 months) in ABC compared with 
GCB-DLBCL, respectively (Dunleavy et al., 2009). It is predictable that bortezomib as an 
inhibitor of NFB pathway will be developed for other cancer therapy.  
4.2 Molecular mechanisms of bortezomib in the treatment of myeloma  
Bortezomib is a dipeptide containing phenylalanine and leucine in which the carboxylic 
group is replaced by a boronic acid group (-RB(OH)2) (Figure 4). 
 
Fig. 4. The chemical structure of bortezomib. Bortezomib is a dipeptide made up of 
phenylalanine and leucine in which boronic acid group replaces the carboxyl group. 
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Bortezomib is a potent inhibitor of proteasomes. Mechanistically, its active boron acid group 
competitively and reversibly binds to the catalytic site of the 26S proteasome with high 
affinity and specificity. Specifically, the boric acid group of bortezomib binds to and blocks 
the catalytic threonine residue in the subunits of the 20S core particle. Inhibition of 
proteasome results in accumulation of several important tumor suppressor proteins, 
including p21, p27, p53, PTEN, and IκBǂ. IκBǂ is an inhibitor of NFκB, the most important 
transcription factor in regulating cell proliferation. Normally, IκBǂ is bound to NFκB and 
inhibits its activity. The IκBǂ stability is regulated via the UPS pathway. Once IκBǂ is 
degraded, NFκB will be librated and translocated into the neucleus where it binds to the 
promoters of various genes and initiates their transcription and expression. IκBǂ/NFκB 
signaling plays a critical role in bortezomib-induced cell apoptosis. Bortezomib also 
interrupts the interaction of Mdm2 and its substrate p53, thus restoring p53 function and 
leading to cell apoptosis. Moreover, bortezomib directly acts on MM cells and alters cellular 
interactions and cytokine secretion in the bone marrow (BM) millieu to inhibit tumor cell 
growth, induce apoptosis, and overcome drug resistance. Specifically, bortezomib inhibits 
the paracrine growth of human MM cells by decreasing their adherence to bone marrow 
stromal cells (BMSCs) and related NFκB-dependent induction of interleukin-6 secretion in 
BMSCs, as well as inhibiting proliferation and growth signaling of residual adherent MM 
cells (Hideshima et al., 2001). 
4.3 Pitfalls of bortezomib in MM treatment 
Although bortezomib has made a great success in the treatment of MM and MCL, it is not a 
perfect drug, and some critical features prevent its application (Kumar and Rajkumar, 2008; 
Oerlemans et al., 2008). Firstly, it is unstable and it retains its activity for 4-8 hrs after re-
constituted, thus having to be used within 8 hours. Secondly, the drug is administrated via 
i.v. injection which should be performed by a nurse at a clinic or in a hospital, which largely 
increases the cost of the health care system.  
Thirdly, the therapeutic window of bortezomib is very narrow. The therapeutic dosage is 1.3 
mg/m2 body surface, it will produce dose-dependent toxicity when the dose reaches 1.5 
mg/m2. These adverse effects and toxicity include myelosuppression which leads to anemia, 
neutropenia and thrombocytopenia, and bortezomib-induced peripheral neuropathy, which 
occurs in more than 30% patients and this kind of neuropathy is sometimes even worse to 
affect patients’ daily activity (Richardson et al., 2006). Although these kinds of adverse 
effects are recoverable when the drug is discontinued, some patients couldn’t endure the 
severe effects. Recent studies suggest that some important genes (such as RHOBTB2 and 
SOX8) involved in the development of the nervous system (especially the peripheral 
nervous system) are upregulated by bortezomib after one cycle therapy (Cavo et al., 2010). 
Lastly, drug resistance is becoming an emerging issue. Although 35% of refractory and 
relapsed myeloma patients are generally responsive after bortezomib treatment, there are only 
4% patients with a complete remission outcome and 65% had no response. There are several 
underlying issues for bortezomib resistance. Firstly, the resistance to bortezomib is associated 
with overexpression of ǃ5 subunits of 20S core particles, which leads to impaired binding of 
bortezomib and decreased proteasome inhibition. For example, K562 cells with a high level of 
ǃ5 are more resistant to bortezomib than other cell lines such as OCI-AML2 expressing low 
levels of 5 (Li et al., 2010). Secondly, bortezomib resistance is also associated with mutations 
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in ǃ5 gene. A DNA sequencing analysis in bortezomib-resistant cells revealed that the G322A 
mutation in PSMB5 gene leads to an Alanine Threonine change, which largely confers 
resistance because threonine is the target of bortezomib (Oerlemans et al., 2008). In a Jurkat cell 
model, mutations such as C323T and G326A are also reported (Lu et al., 2008). Thirdly, 
overexpression of other anti-apoptotic genes such as PSMD4 (Shaughnessy et al., 2010), a non-
ATPase subunit of the proteosomal 19S regulator, and heat shock protein 27 (HSP27) 
(Chauhan et al., 2003), an important gene protecting cell against apoptosis, are also found to be 
associated with resistance to bortezomib. Recently, an siRNA screen identified several 
important molecular modulators that sensitize bortezomib-induced cell apoptosis, including 
proteasome subunits PSMA5, PSMB2, PSMB3, and PSMB7 (Zhu et a., 2011), this is quite 
reasonable because these genes directly modulate the proteasome function. To be noted, the 
Cyclin-dependent kinase 5 (CDK5) and other 11 genes were also identified from this screen, 
but their detailed roles in bortezomib-induced cell death are yet to be studied. A most recent 
study demonstrated that impaired bortezomib binding to mutant ǃ5 subunit of the 
proteasome is the underlying basis for bortezomib resistance in leukemia cells, while 
proteasome subunit overexpression is an essential compensatory mechanism for the impaired 
catalytic activity of these mutant proteasomes (Franke et al., 2011). 
5. Development of novel proteasomal inhibitors 
Currently, several classes of novel proteasome inhibitors have been developed and some 
have been moved to advanced clinical trials for the treatment of various blood cancers, such 
as leukemia, lymphoma, and myeloma. Although they share some common features, these 
novel inhibitors of proteasomes could be classified as: highly selective and irreversible, 
orally active, non-competitive, and natural products. The details are shown in Table 1. 
5.1 Highly selective and irreversible novel inhibitors of proteasomes 
Several promising novel proteasomal inhibitors have been extensively investigated in vivo, 
in vitro, and in clinical settings. Compared with bortezomib, these agents are highly selective 
and irreversible, such as carfilzomib, NPI-0052, and PI-083.  
5.1.1 Carfilzomib 
Carflizomib, or PR-171, is a tetrapeptide epoxyketone and a selective and irreversible 
proteasome inhibitor that primarily targets the chymotrypsin-like (CT-L) subunits in both the 
constitutive proteasome (c20S, 5) and the immunoproteasome (i20S, LMP7) (Parlati et al., 
2009). Inhibition of proteasome-mediated proteolysis results in an accumulation of 
polyubiquitinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and 
inhibition of tumor growth. Compared with bortezomib, carfilzomib displays minimal cross 
reactivity on off-target enzymes, good tolerability and little side effects in multiple open-label 
clinical trials (O'Connor et al., 2009). In patients with relapsed or refractory multiple myeloma, 
twice-weekly consecutive-day single-agent carfilzomib 20 mg/m2 , escalating to 27 mg/m2 the 
second cycle was associated with a 54% overall response rate in bortezomib-naive patients and 
a 26% overall response rate in bortezomib and immunomodulatory drug refractory patients. 
The overall response rate is 20% higher than that with single bortezomib treatment. The U.S. 
Food and Drug Administration has granted fast track designation for carfilzomib to develop as 
a potential treatment of patients with relapsed and refractory multiple myeloma. 
www.intechopen.com
 
Hematology – Science and Practice 
 
506 
Drugs Features R&D Stage Institutes 
Highly selective and irreversible 
Carfilzomib (PR-171) Epoxomicin analog 
Minimal activity against off-target 
enzymes 
Lymphoid neoplasms and multiple 
myeloma 
Phase III for 
MM 
Phase I for 
solid tumors 
Proteolix  
Onyx 
Marizomib 
 (NPI-0052 
Salinospormide A) 
Marine product, -lactone-Ǆ-lactam 
family 
More potent than Bortezomib 
MM, lymphomas, leukemias and solid 
tumors 
Phase II for 
myeloma 
Nereus 
Pharmaceutica
ls, Inc. 
PI-083 From Streptomyces matensis  
Thr21,Gly47, Ala 49 of 5, Asp114 of 
6 
Cancer-selective proteasome inhibitor 
Myeloma, lung cancer, breast cancer 
Preclinical Moffitt Cancer 
Center 
Orally active 
CEP-18770 Boronic-acid based 
More sustained Pharmacodynamics 
Competes with bortezomib 
Few side effects during treatment 
Phase II for 
myeloma 
Cephalon 
PR-047 c20S, i20S 
>80% inhibition in most tissues 
High oral bioavailability 
 Proteolix  
 
Non-comparative inhibitors on 20S proteasomes 
Clioquinol Binding to a subunits of 20S  
Non-competitive inhibition 
Overcome resistance to Bortezomib 
Phase I University 
Health 
Network 
5-Amino-8-
hydroxyl-quine 
(5AHQ) 
Natural Products 
Pristimerin Isolated from Celastrus and Maytenus 
spp. 
Tripernoid family 
C6 of Pristimerin interacts with 
hydroxyl group of N-terminal Thr of  
c20S 
Inhibits IKK, suppresses NFB, cyclin 
D 
Preclicical Mayo Clinic 
EGCG (-)-
epigallocatechin-3-
gallate 
From green tea 
Ester bond of EGCG attacked by N-
terminal Thr of 20S 
Competitively inhibits Proteasome 
with Bortezomib 
Preclinical Not available 
Table 1. Novel Proteasome inhibitors against blood cancers 
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5.1.2 Marizomib  
Marizomib (NPI-0052 or salinosporamide A) is a structurally and pharmacologically unique 
ǃ-lactone-Ǆ-lactam proteasome inhibitor produced by a marine actinomycete Salinispora 
tropica (Macherla et al., 2005). Unlike bortezomib, marizomib irreversibly binds to 
proteasomes and inhibits all three protease activities, including chymotrypsin-like (CT-L, 
5), trypsin-like (T-L, 2), and caspase-like (C-L,1). This nature is responsible for its slower 
efflux, longer duration of action, and greater cytotoxicity (Obaidat et al.). Preclinical studies 
suggest that marizomib is a more potent inducer of apoptosis in myeloma cells than 
bortezomib, and demonstrates activity in bortezomib resistant cell lines as well. In addition 
to MM, marizomib has been evaluated in models for MCL, Waldenstrom's 
macroglobulinemia (WM), chronic and acute lymphocytic leukemia, glioma, colorectal and 
pancreatic cancers, and has exhibited synergistic activities in tumor models in combination 
with bortezomib, and various histone deacetylase inhibitors (B et al., 2011; Singh et al., 
2010). Marizomib has been moved to Phase II clinical trials and achieved very good 
responses. In a Phase I study of 17 patients with relapsed and relapsed/refractory multiple 
myeloma, Drug- related adverse events have consisted principally of mild-to-moderate 
fatigue, nausea and diarrhea. More importantly, NPI-0052 does not appear to induce 
peripheral neuropathy or myelosuppression associated with bortezomib treatment 
(Hofmeister et al., 2009).  
5.2 Orally active inhibitors of proteasomes: CEP-18770, PR-047 and ONX-0912 
The i.v. administration of bortezomib largely increases the workload of the physicians and 
other medical staff and largely increases the healthcare budget. Therefore, orally active 
inhibitors of proteasomes are of great interest. Currently, several such orally active drugs 
have been developed, including CEP-18770, PR-047 and ONX-0912. 
5.2.1 CEP-18770 
CEP-18770 is a novel orally-active inhibitor of the chymotrypsin-like activity of the 
proteasome that down-modulates the NFactivity (Piva et al., 2008). CEP-18770 induces 
apoptotic cell death in MM cell lines and in primary purified CD138-positive explant 
cultures from untreated and bortezomib-treated MM patients. Importantly, CEP-18770 
exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow 
progenitors, and bone marrow-derived stromal cells. Both intravenous and oral 
administration of CEP-18770 resulted in a sustained pharmacodynamic inhibition of 
proteasome activity in tumors relative to normal tissues, complete tumor regression of MM 
xenografts and improved overall median survival in a systemic model of human MM. In 
addition, CEP-18770 has a strong antiangiogenic activity in vitro, and potently represses 
RANKL-induced osteoclastogenesis. A recent study suggests that CEP-18770 enhances  
the anti-myeloma activity of bortezomib and melphalan which suggests a  
combinatorial regimen for MM therapy (Piva et al., 2008; Sanchez et al., 2010). This agent 
has moved to clinical trials for relapsed or refractory multiple myeloma 
(http://clinicaltrials.gov/ct2/show/NCT01348919) or for solid tumors and non-Hodgin’s 
lymphomas (http://clinicaltrials.gov/ct2/show/NCT00572637). 
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5.2.2 PR-047 
PR-047 is also an orally active inhibitor that selectively inhibits CT-L activity of both the 
constitutive proteasome (5) and immunoproteasome (LMP7) and demonstrated an 
absolute bioavailability of up to 39% in rodents and dogs. It was well tolerated with 
repeated oral administration at doses resulting in >80% proteasome inhibition in most 
tissues and elicited an antitumor response equivalent to intravenously administered 
carfilzomib in multiple human tumor xenograft and mouse syngeneic models (Zhou et al., 
2009). The favorable pharmacologic profile supports its further development for the 
treatment of malignant diseases. 
5.2.3 ONX-0912 
Like carfilzomib, ONX-0912 is also an epoxyketone compound with novel selective, 
irreversible inhibition activity to the immunopreteasome and constituent 20S particles. 
ONX-0912 displays great oral activity (Chauhan et al., 2010). Primary WM cells expressing 
higher level of 20S are more responsive to ONX-0912 (Roccaro et al., 2010). ONX-0912 
induces WM cell apoptosis through c-JNK activation, NFB inhibition, caspase cleavage, 
and initiation of the unfolded protein response. Moreover, ONX-0912 also reduce the 
secretion of BM-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1), thus 
inhibiting BM-induced Akt phosphorylation and phosphorylated extracellular signal-related 
kinase activation in WM cells. In addition to blood cancers, ONX-0912 also displays potent 
anticancer activity in solid tumors and a Phase I study of ONX 0912 administered orally in 
patients with advanced refractory or recurrent solid tumors is under evaluation 
(http://clinicaltrials.gov/ ct2/show/NCT01129349). 
5.3 Non-classic inhibitors: Clioquinol and 5-amino-8-hydroxyl-quinoline 
Most of the proteasomal inhibitors competitively bind to the subunits of 20S proteasome, 
for example, MG-132, bortezomib, and carfilzomib. Recently, we found that a group of 
quinoline-based agents including clioquinol, chloroquine, 5-amino-8-hydroxyl quinoline 
(5AHQ), and metfloquinoline display potent inhibition on proteasomal catalytic activity by 
a non-competitive manner (Li et al., 2010; Mao et al., 2009). Further studies indicated that 
these agents bind to the  subunits other than  subunits of the 20S core particle as 
bortezomib or MG-132 does. In analysis of its binding to purified 20S archaeal proteasomes 
from Thermoplasma acidophilium by using nuclear magnetic resonance (NMR) technology, 
chloroquine binds to the subunits with 260 Å distance from  active sites. Notably, 
chloroquine and MG132 can bind the proteasome simultaneously, further establishing that 
they exploit two completely separate binding pockets (Sprangers et al., 2008). 
The interaction of 5AHQ with produced clear spectral changes localized to residues 
Ile159, Val113, Val87, Val82, Leu112, Val89, Val134, Val24 and Leu136, which are inside the 
antechamber. In contrast, MG132 which binds the proteolytic chamber produces shifts in the 
beta rings of the full proteasome. Binding to the subunit, 5AHQ leads to a conformational 
change of the core particle and displays a non-competitive inhibition on proteasome. 5AHQ 
preferentially induced cell death in primary myeloma and leukemia cells compared with 
normal hematopoietic cells. More importantly, 5AHQ overcomes the resistance to 
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bortezomib and is equally cytotoxic to human myelomonocytic leukemia THP1/BTZ500 
cells which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of 
the overexpression and mutation of the bortezomib-binding5 subunits (Li et al., 2010). 
Therefore, a group of quinoline-based small molecules can inhibit proteasomal activity in a 
non-cannoical manner. Because of their low toxicity and novel inhibition mechanism, these 
compounds could be developed for MM and leukemia therapy. Currently, clioquinol has 
been moved to clinical trials for refractory acute myeloid leukemia. 
5.4 Natural proteasomal inhibitors: Pristimerin and EGCG 
Except for small chemical compounds or peptide reagents, several natural products have 
been identified and evaluated for MM treatment in both in vivo and in vitro assays. The most 
promising candidate could be NPI-0052 or marizomib isolated from a marine actinomycete 
Salinispora tropica as described above. Here we discuss two more agents in this category 
pristimerin and (-)-epigallocatechin-3-gallate (EGCG). 
5.4.1 Prisitmerin 
Pristimerin belongs to the tripernoid family and is isolated from a traditional Chinese 
medicine called Celastrus and Maytenus spp. Nucleophilic susceptibility and in silico docking 
studies show that C6 of pristimerin is highly susceptible towards a nucleophilic attack by the 
hydroxyl group of N-terminal threonine of the proteasomal chymotrypsin subunit. This 
interaction leads to an inhibition of the chymotrypsin-like activity of a purified rabbit 20S 
proteasome (Yang et al., 2008). Pristimerin displayed similar inhibition activity in purified 
rabbit 20S proteasomes and in human prostate cancer cell lysates (Tiedemann et al., 2009). The 
IC50s are 2.2 and 3.0 in vitro and in vivo, respectively. The treatment of pristimerin in 
prostate cancer cells resulted in the accumulation of ubiquitinated proteins and three 
proteasome target proteins, Bax, p27 and B. However, myeloma cells are more sensitive to 
pristimerin. Pristimerin potently inhibits both IKK and the proteasome in MM cells with an 
IC50 of 100 nM. Pristimerin causes overt suppression of constitutive NFκB activity in myeloma 
cells that may mediate its suppression of cyclin D, thus inducing myeloma cell apoptosis. 
5.4.2 (-)-epigallocatechin-3-gallate (EGCG) 
EGCG is one of the polyphenols found in green tea extract and inhibits proteasomal activity 
(Golden et al., 2009). The ester bond of EGCG is attacked by the N-terminal threonine residue 
of the proteasome, forming a covalent EGCG-proteasome complex which has been confirmed 
by high performance liquid chromatography (HPLC) analysis. Recent studies found that 
EGCG competitively inhibits proteasomal activity in a same manner as bortezomib does, thus 
neutralizing the inhibiting activity of bortezomib and other boronic acid-based proteasome 
inhibitors. Therefore, green tea polyphenols block the anticancer effects of bortezomib and 
green tea is not encouraged for myeloma patients who are using bortezomib (Golden et al., 
2009). However, a recent study didn’t find antagonism of bortezomib in preclinical in vivo 
experiments, where EGCG or ascorbic acid plasma concentrations are commensurate with 
dietary or supplemental intake and suggest that patients receiving bortezomib treatment do 
not need to avoid normal dietary consumption of green tea, vitamin C-containing foods, or 
EGCG or vitamin C dietary supplements (Bannerman et al., 2011). 
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6. Targeting at ubiquitination and deubiquitination systems for blood cancer 
treatment 
Proteasomes are critical components of both cancer cells and normal tissues because they 
determine the fate of most of the proteins and therefore inhibition of proteasome will also lead 
to normal cell stress and apoptosis. Thus inhibition of proteasomes indiscriminately raises 
levels of hundreds of proteins regardless to their anticancer effect. Thus, proteasomal 
inhibitors are a double-edged sword because they kill cancer cells, simultaneously, kill normal 
cells. Because proteasome-coupled protein ubiquitination is more specific, inhibition of certain 
enzymes involved in protein ubiquitination will be a more pertinent target for cancer drug 
development. There are four kinds of enzymes, E1, E2, E3 and Dubs which contain thousands 
of members in total. Currently, with the exception of E2, inhibitors of these other enzymes 
have been identified and are being evaluated for the treatment of hematological malignancies.  
6.1 Targeting at E1 for hematological malignancies 
E1 or Ubiquitin-activating enzyme (UBA) controls the protein ubiquitination by activating 
ubiquitin using ATP as an energy supplier. Knockdown of E1 by small interfering RNA 
(siRNA) strategy decreases the abundance of ubiquitinated proteins in leukemia and 
myeloma cells and induced cell death (Xu et al., 2010). Blood cancer cells including leukemia 
and myeloma are more sensitive to E1 inhibitors. A small molecule PYZD-4409, an inhibitor 
of E1, can abolish protein ubiquitination, thus inducing endoplasmic reticulum (ER) stress, 
and leading to cancer cell apoptosis. PYZD-4409 also displayed ideal anti-leukemia activity 
in vivo without untoward toxicity by decreasing tumor volume and weight (Xu et al., 2010). 
However, the same concern may arise as that already seen in bortezomib because there is 
only a single E1 protein in humans.  
6.2 Targeting at E3 for blood cancer therapies 
The E3 ligases are the largest family in the UPS system. E3s are the primary determinant of 
substrate specificity and represent the largest and most diverse class of Ub/Ub-like 
regulatory enzymes. There are 600-1000 potential E3s responsible for E2 binding, substrate 
recognition, and regulatory functions. Targeting the ubiquitin ligases promises more 
specificity because most E3s tag only a few proteins for destruction. Such drugs can, in 
theory, block degradation of its specific substrate proteins. Currently, interfering with E3-
substrate interaction is one of the leading strategies for anti-cancer drugs targeting at UPS. 
One of the most promising E3s is Skp2, the F-box protein that controls degradation of p27, 
an important tumor suppressor gene (Zhan et al., 2007).  Skp2 levels are abnormally high in 
leukemia and myeloma cells, therefore, blocking Skp2 activity might reasonably be expected 
to stop cancer cell proliferation. CpdA is such an inhibitor of Skp2 by preventing 
incorporation of Skp2 into the SCF Skp2 ligase, CpdA induces G1/S cell-cycle arrest as well 
as SCF Skp2- and p27-dependent cell killing (Chen et al., 2008). In models of MM, CpdA 
overcomes resistance to dexamethasone, doxorubicin, and melphalan, as well as to 
bortezomib, and also acted synergistically with this proteasome inhibitor. Importantly, 
CpdA is active against patient-derived plasma cells and both myeloid and lymphoblastoid 
leukemia blasts, and showed preferential activity against neoplastic cells while relatively 
sparing other marrow components (Chen et al., 2008).  
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Another interesting E3 is MdM2 which regulates p53 ubiquitination. Several inhibitors of 
MdM2 have been identified, such as Nutlins (Stuhmer et al., 2005) and MI-63 (Ding et al., 
2006; Samudio et al., 2010). By disrupting the interaction of MdM2 and p53, both Nutlins 
and MI-63 can restore p53 which further tends to promote arrest of cell cycle and apoptosis. 
These drugs are effective in inducing apoptosis of MM cells which express wild-type p53, 
unfortunately, it won’t work in cancer cells with mutated or deleted p53.   
6.3 Targeting at deubiquitinases 
Just like E3s, deubiquitinases play a tumor-suppressing or -promoting role dependent on its 
targeting protein. For example, USP9X is an oncoprotein enzyme that removes ubiquitin 
from the anti-apoptotic protein MCL-1 (Sun et al., 2011). MCL1 is overexpressed in most 
blood cancer cells, and is highly associated with cancer cell proliferation and protects cancer 
cells from apoptosis (Sun et al., 2011). MCL1 is degraded by proteasomes after poly-
ubiquitination. High expression of USP9X is seen in leukemia and MM cells. A small 
molecule called WP1130 (Kapuria et al., 2010) has been identified as a partly selective Dub 
inhibitor by directly inhibiting activity of USP9x, USP5, USP14, and UCH37, which are 
known to regulate survival protein stability and 26S proteasome function. WP1130-
mediated inhibition of tumor-activated Dubs results in downregulation of antiapoptotic and 
upregulation of proapoptotic proteins, such as Mcl-1 and p53, thus leading to cancer cell 
death (Kapuria et al., 2010).  
Although large-scale inhibitors of ubiquitination enzymes are yet to fully develop, 
successful E3 and Dub inhibitors have established the proof-of-principle that inhibition of 
ubquitinating/deubiquitinating enzymes is novel and potentially powerful strategy to 
develop anti-blood cancer drugs and is surely an area that will expand greatly in the future.  
7. Summary  
The ubiquitin-proteasome system has been widely investigated in the association of 
hematological malignancies, it is extensively involved in the development and therapy of 
blood cancers, including leukemia, lymphoma and multiple myeloma. Targeting at the UPS 
specific genes/proteins, several novel drugs have been developed including the first-
approved proteasome inhibitor-bortezomib in the treatment of myeloma and mantle cell 
lymphoma. The upcoming years will witness the introduction of more potent and more 
patient-friendly next generations of UPS inhibitors such as carfilozomib and inhibitors of 
ubiquitinating/deubiquitinating enzymes for the treatment of blood cancer patients.  
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